211 related articles for article (PubMed ID: 30077698)
1. Risk of Major Bleeding with Ibrutinib.
Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
[TBL] [Abstract][Full Text] [Related]
2. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Jones JA; Hillmen P; Coutre S; Tam C; Furman RR; Barr PM; Schuster SJ; Kipps TJ; Flinn IW; Jaeger U; Burger JA; Cheng M; Ninomoto J; James DF; Byrd JC; O'Brien SM
Br J Haematol; 2017 Jul; 178(2):286-291. PubMed ID: 28397242
[TBL] [Abstract][Full Text] [Related]
3. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Shatzel JJ; Olson SR; Tao DL; McCarty OJT; Danilov AV; DeLoughery TG
J Thromb Haemost; 2017 May; 15(5):835-847. PubMed ID: 28182323
[TBL] [Abstract][Full Text] [Related]
5. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Tillman BF; Pauff JM; Satyanarayana G; Talbott M; Warner JL
Eur J Haematol; 2018 Apr; 100(4):325-334. PubMed ID: 29285806
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
Aguilar C
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
[TBL] [Abstract][Full Text] [Related]
9. Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials.
Yun S; Vincelette ND; Acharya U; Abraham I
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):31-37.e13. PubMed ID: 27780690
[TBL] [Abstract][Full Text] [Related]
10. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Brown JR; Moslehi J; Ewer MS; O'Brien SM; Ghia P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Coutre SE; Dilhuydy MS; Cramer P; Jaeger U; Dreyling M; Byrd JC; Treon S; Liu EY; Chang S; Bista A; Vempati R; Boornazian L; Valentino R; Reddy V; Mahler M; Yang H; Graef T; Burger JA
Br J Haematol; 2019 Feb; 184(4):558-569. PubMed ID: 30506764
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A
Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171
[TBL] [Abstract][Full Text] [Related]
12. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
14. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Georgantopoulos P; Yang H; Norris LB; Bennett CL
Cancer Med; 2019 May; 8(5):2233-2240. PubMed ID: 30983123
[TBL] [Abstract][Full Text] [Related]
15. Management of adverse effects/toxicity of ibrutinib.
Paydas S
Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
[TBL] [Abstract][Full Text] [Related]
16. Perioperative Bleeding Associated With Ibrutinib in Dermatologic Surgery: A Case-Control Study.
Aghazadeh N; Jin MF; Pride RL; O'Byrne J; Vidal NY
Dermatol Surg; 2022 Nov; 48(11):1166-1170. PubMed ID: 36095288
[TBL] [Abstract][Full Text] [Related]
17. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
19. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
Chai KL; Rowan G; Seymour JF; Burbury K; Carney D; Tam CS
Leuk Lymphoma; 2017 Dec; 58(12):2811-2814. PubMed ID: 28504030
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
